Loading
A phase 2 trial of AK146D1 in advanced solid tumours, run by Akeso, now recruiting.
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer is a phase 2 interventional study registered as NCT07591090 by Akeso, with 200 participants planned, started 2026-07-17 and due to reach its primary completion in 2027-09-01. Interventions recorded: AK146D1 for injection and AK112 Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/